Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about how well a chemotherapy regime including
rituximab works in treating patients with Burkitt or atypical Burkitt lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital